Cancer Database Query Results

Scientific Papers found: Click to Expand⟱

MF,

Extremely low frequency electromagnetic field (ELF-EMF) reduces oxidative stress and improves functional and psychological status in ischemic stroke patients

Trial,

Stroke,

ELF-EMF field of 40 Hz, 7 mT for 15 min/day for 4 weeks (5 days a week)

post-stroke patients. Fifty-seven

*antiOx↑, *cognitive↑, *Dose↝,

4097-

MF,

Theta Frequency Electromagnetic Stimulation Enhances Functional Recovery After Stroke

Trial,

Stroke,

mice

*motorD↑, *eff↑, *Dose↝,

4095-

MF,

Frequency-tuned electromagnetic field therapy improves post-stroke motor function: A pilot randomized controlled trial

Trial,

Stroke,

*Dose↝, *motorD↑,

3478-

MF,

One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study

Trial,

BC,

in-vitro,

BC,

MCF7

in-vitro,

Nor,

C2C12

TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,

8468-

Mg,

The effect of long-term magnesium intake on inflammatory markers in patients with metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials

Trial,

Obesity,

*CRP↓,

8457-

Mg,

The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial

Trial,

AD,

*Dose?, *cognitive↑, *memory↑, *RT↓, *Sleep↑, *toxicity↓, *rHR↓, *HRV↑,

8458-

Mg,

Magnesium treatment increases gut microbiome synthesizing vitamin D and inhibiting colorectal cancer: results from a double-blind precision-based randomized placebo-controlled trial

Trial,

CRC,

Of 239 participants who completed the trial, 226 with valid microbiome data were analyzed

*GutMicro↑, *VitD↑, Risk↓,

8462-

Mg,

Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study

Trial,

Nor,

*BioAv↑,

8470-

Mg,

The Effects of Magnesium and Zinc Co-Supplementation on Biomarkers of Inflammation and Oxidative Stress, and Gene Expression Related to Inflammation in Polycystic Ovary Syndrome: a Randomized Controlled Clinical Trial

Trial,

Nor,

Polycystic Ovary Syndrome

*Dose?, *CRP↓, *PCO↓, *TAC↑, *IL1↓, *TNF-α↓,

8473-

Mg,

Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial

Trial,

Nor,

 A total of 62 men and non-pregnant women aged 18-65 year, with new diagnosis of prediabetes (glucose 5.6 <7.0 mmol/L and/or post-load glucose ≥7.7 <11.1 mmol/L) and hypomagnesemia (

*Dose↝, *hs-CRP↓,

8475-

Mg,

Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep

Trial,

Nor,

*Dose↝, *Obesity↓, *CRP↓,

782-

Mg,

Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial

Trial,

Var,

*BioAv↑,

3851-

MSM,

Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial

Trial,

Arthritis,

3g twice a day

*Pain↓, *QoL↑,

2934-

NAD,

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

Trial,

Nor,

80 participants

*Dose↑, *Strength↑,

5606-

NaHCO3,

Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer

Trial,

PC,

Twenty-eight patients with metastatic or recurrent pancreatic cancer were assessed in this study

Dose↝, OS↑, eff↑,

5605-

NaHCO3,

A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis

Trial,

HCC,

57 patients with large HCC) and a randomized controlled (20 patients with large HCC) study.

eff↑, Dose↝, other↓, OS↑, toxicity↓, AntiCan↓,

5255-

NCL,

Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: A three-part randomized, double-blind, placebo-controlled trial

Trial,

Nor,

Twenty-eight healthy subjects were enrolled in part A (12 subjects), part B (4 subjects), and part C (12 subjects), all completed the study according to protocol.

BioAv↝, Dose↝, toxicity↓, BioAv↑, BioAv↝,

7707-

NIV,

lpi,

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial

Trial,

RCC,

OS↑, Dose↝,

7534-

OLE,

An oleuropein-based dietary supplement may improve joint functional capacity in older people with high knee joint pain: findings from a multicentre-RCT and post hoc analysis

Trial,

Arthritis,

*Pain↓, *Dose↝,

4648-

OLEC,

The Effect of Dietary Intervention With High-Oleocanthal and Oleacein Olive Oil in Patients With Early-Stage Chronic Lymphocytic Leukemia: A Pilot Randomized Trial

Trial,

CLL,

40 ml/day of high OC/OL-EVOO (416 mg/Kg OC and 284 mg/kg OL)

Apoptosis↑, *QoL↑,

8441-

OM,

The effect of Origanum majorana tea on motor and non-motor symptoms in patients with idiopathic Parkinson's disease: A randomized controlled pilot study

Trial,

Park,

Sixty patients with idiopathic Parkinson's disease and under conventional medication were enrolled voluntarily in the study.

*NMSS↓, *BDI↓, *UPDRSIII∅, *motorD↑,

8447-

OM,

Inhalation of Origanum majorana L. essential oil while working reduces perceived stress and anxiety levels of nurses in a COVID-19 intensive care unit: a randomized controlled trial

Trial,

Nor,

*Dose?, *ANXi↓, *Stress↓,

2075-

PB,

Chemo,

Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival

Trial,

CRC,

OS↑, HDAC↓,

2026-

PB,

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study

Trial,

GBM,

Twenty-three patients with supratentorial recurrent malignant gliomas were enrolled on this dose escalation trial

Dose↝, Dose↑, Dose↝, OS↑, HDAC↓, TumCCA↑, P21↑, other↝, BioAv↑, eff↑,

2027-

PB,

Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors

Trial,

Var,

TumCG↓, Dose↝, toxicity↓, Dose↝, HDAC↓, OS↑,

2038-

PB,

A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies

Trial,

Var,

Dose∅, *toxicity↝, BioAv↑, SD↑,

1669-

PBG,

Chemo,

Antioxidant and anti-inflammatory effects of oral propolis in patients with breast cancer treated with chemotherapy: a Randomized controlled trial

Trial,

BC,

250 mg/ twice daily for 3 months

Breast cancer patients receiving chemotherapy were randomly assigned to two groups; a week prior to chemotherapy, the first group received Propolis (250 mg/ twice daily for 3 months) and the second group received a placebo daily.

antiOx↑, Inflam↓,

4924-

PEITC,

Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial

Trial,

Oral,

 consumed 200 g of Nutri-Jelly with and without 20 mg of PEITC

QoL↑, P53↑, OS↑, Cyt‑c↝, other↝, ROS↑, selectivity↑, P21↑, TumCCA↑, Dose↝, BioAv↑, Weight↑, chemoP↑,

4938-

PEITC,

Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers

Trial,

Nor,

 1-week treatment period, each subject took PEITC (10 mg in 1 mL of olive oil, 4 times per day).

*Risk↑, *P450↓, *BioAv↑, *BioAv↑, *BioAv↑, *Dose↝, Dose↝,

6874-

Phen,

Blueberry phenolics are associated with cognitive enhancement in supplemented healthy older adults

Trial,

Nor,

(90 days) supplementation of freeze-dried BB (24 g d-1, equivalent to 1 cup of fresh BB)

*other↑, *cognitive↑, *Dose↝,

5630-

ProBio,

Bif,

EFFICACY OF PROBIOTICS IN PREVENTING CHEMOTHERAPY-INDUCED DIARRHEA IN GASTROINTESTINAL CANCER PATIENTS

Trial,

GC,

Dose↝, Diar⇅,

5624-

ProBio,

Bif,

A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer

Trial,

Testi,

Fifty-two patients with colorectal cancer were randomized at four weeks after surgery to receive either a placebo

Dose↝, TNF-α↓, IL6↓, IL10↓, IL12↓, IL22↓, toxicity↓,

3915-

PS,

Positive effects of soy lecithin-derived phosphatidylserine plus phosphatidic acid on memory, cognition, daily functioning, and mood in elderly patients with Alzheimer's disease and dementia

Trial,

AD,

 (300 mg PS + 240 mg PA/day) or placebo

*memory↑, *cognitive↑, *Half-Life↝, *Mood↑,

3914-

PS,

Soybean-Derived Phosphatidylserine Improves Memory Function of the Elderly Japanese Subjects with Memory Complaints

Trial,

AD,

(100 mg, 300 mg/day) or placebo for 6 months.

*memory↑, *cognitive↑, *lipid-P↓, *antiOx↑, *Inflam↓,

6879-

PS,

aLinA,

Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial

Trial,

Nor,

190 participants (mean [SD] age, 67.95 [5.62] years;

*Dose↝, *cognitive↑, *memory↑, *DHA↑, *EP2↑, *Ach↑,

3925-

PTS,

Analysis of Safety from a Human Clinical Trial with Pterostilbene

Trial,

NA,

*toxicity↓, *Half-Life↑, *BioAv↑,

3606-

QC,

The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial

Trial,

Arthritis,

500 mg/day

50 women with RA

*motorD↑, *Pain↓, *TNF-α↓, *IL8↓, *IL6↓, *IL1β↓, *NF-kB↓, *p38↓,

3611-

QC,

Quercetin and vitamin C supplementation: effects on lipid profile and muscle damage in male athletes

Trial,

Nor,

60 males for eight weeks

*eff↝, *LDH↓,

3334-

QC,

Pharmacokinetics of Quercetin Absorption from Apples and Onions in Healthy Humans

Trial,

Nor,

*Half-Life↑,

7576-

Rad,

HPT,

Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group

Trial,

Nor,

 306 patients randomized.

RadioS↑,

5969-

Rad,

CET,

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

Trial,

HNSCC,

Dose↝, radioP↑, OS↑,

5971-

Rad,

CET,

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Trial,

HNSCC,

OS↑,

5268-

Ramu,

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)

Trial,

HCC,

other↝,

5285-

Ramu,

docx,

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Trial,

NSCLC,

OS↑,

5788-

RES,

Calorie restriction-like effects of 30 days of Resveratrol (resVida™) supplementation on energy metabolism and metabolic profile in obese humans

Trial,

Nor,

11 healthy, obese men with placebo and 150 mg/day resveratrol in a randomized double-blind cross-over study for 30 days.

*AMPK↑, *SIRT1↑, *PGC-1α↑, *BP↓, *CRM↑, *Dose↝, *mtDam↓, *ALAT↓, *hepatoP↑,

6810-

RF,

SUMMARY OF SAFETY AND PROBABLE BENEFIT (SSPB)

Trial,

HCC,

Dose↝, Dose↝, Dose↝, OS↑,

6808-

RF,

Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma

Trial,

HCC,

OS↑, *toxicity↓, Dose↝, TumCG↓, Dose↝, Dose↝, Dose↝, eff↑,

3621-

RosA,

Short-Term Study on the Effects of Rosemary on Cognitive Function in an Elderly Population

Trial,

AD,

Twenty-eight older adults (mean age, 75 years)

*cognitive↑, *Dose↝, *BioAv↑,

3638-

Sage,

Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial

Trial,

AD,

(60 drops/day

*cognitive↑,

3939-

SAMe,

VitB12,

ALC,

Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study

Trial,

NA,

 Participants were 73 serotonin reuptake inhibitor (SRI) nonresponders with major depressive disorder

*cognitive↑, *Mood↑,

Showing Research Papers: 351 to 400 of 435
Prev Page 8 of 9 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 435

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

12-HETE↓, 1, 2/16-OHE1↑, 1, 5-HETE↓, 1, AcOH↑, 2, AntiBio↑, 2, BDI↓, 1, Buty↑, 3, CCr / CrCl↓, 1, CCr / CrCl∅, 1, Eic↓, 1, END↑, 1, ENL↑, 1, Eos↓, 1, FEV1↑, 2, FFA/NEFA↝, 1, HRV↑, 1, IgE↓, 1, Ingr↝, 1, IPSS↓, 1, Learn↑, 1, NLR↓, 1, NMSS↓, 1, PA↑, 2, PCO↓, 1, PEF↑, 1, rHR↓, 1, RT↓, 2, SCFAs↑, 3, SCFAs∅, 1, Stress↓, 4, Tinn↓, 1, TMAO∅, 1, UFR↑, 1, UPDRS↓, 1, UPDRSIII∅, 1, UR↓, 1,

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 2, antiOx↑, 11, Bil↓, 2, Catalase↑, 1, GPx↑, 1, GSH↑, 5, HDL↓, 2, HDL↑, 4, HO-1↑, 1, Iron↓, 1, lipid-P↓, 2, MDA↓, 4, MDA↑, 1, MPOD↑, 2, NRF2↑, 2, ROS↓, 16, SAM-e↓, 1, SOD↑, 3, TAC↑, 3, TBARS↓, 1, uricA↓, 1,

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,

Mitochondria & Bioenergetics(tgid=3) ⓘ

mitResp↑, 1, mtDam↓, 1, PGC-1α↑, 1,

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 1, adiP↑, 1, ALAT↓, 3, ALAT∅, 1, AMPK↑, 1, CRM↑, 1, DHA↑, 2, glucose∅, 1, KeyT↝, 1, lactateProd↓, 1, LDH↓, 3, LDL↓, 9, NH3↓, 1, SIRT1↑, 1,

Cell Death(tgid=5) ⓘ

BAX↓, 1, Casp3↓, 1, CK2↓, 1, p38↓, 1,

Transcription & Epigenetics(tgid=7) ⓘ

Ach↑, 2, AntiThr↑, 3, other?, 3, other↓, 3, other↑, 16, other↝, 14, other∅, 1,

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1, DNArepair↑, 1, DNMT3A↑, 1,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Choline↑, 1, Diff↝, 1, EP2↑, 1, HDAC3↓, 1, IGF-1↓, 1, IGF-1↑, 1, IGFBP3↓, 1, NOTCH↓, 1, Wnt↓, 1,

Migration(tgid=13) ⓘ

AntiAg↑, 4, AntiAg∅, 1, MMP9↓, 1, TGF-β↑, 1,

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1, TXA2↓, 1, VEGF↑, 1,

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1, IBI↑, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1, COX1↓, 1, CRP↓, 4, IFN-γ↓, 1, IFN-γ↑, 3, IL1↓, 1, IL10↓, 1, IL10↑, 1, IL10∅, 1, IL12↓, 1, IL17∅, 1, IL1β↓, 5, IL4↑, 1, IL4∅, 1, IL6↓, 9, IL8↓, 1, Imm↑, 5, Inflam↓, 23, MCP1/CCL2↓, 1, MCP1/CCL2↝, 1, NF-kB↓, 1, NK cell↑, 3, PGE2↓, 2, PSA↓, 1, TNF-α↓, 8, TNF-α↑, 3, VitD↑, 1,

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 3, AChE↓, 4, BDNF↑, 7, BDNF∅, 1, BrainVol↑, 1, BrainVol↝, 1, BrainVol∅, 3, GABA↑, 1, tau↓, 3, p‑tau↓, 1,

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 10, Aβ∅, 1, BACE/β-secretase↓, 1,

Hormonal & Nuclear Receptors(tgid=20) ⓘ

cortisol↓, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4, BioAv↑, 18, BioAv↝, 12, Dose?, 6, Dose↓, 1, Dose↑, 7, Dose↝, 111, eff↓, 1, eff↑, 21, eff↝, 7, eff∅, 1, Half-Life↓, 2, Half-Life↑, 2, Half-Life↝, 19, P450↓, 1,

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 3, ALAT∅, 1, Albumin↑, 2, ALP↓, 1, AST↓, 1, AST∅, 1, Bil↓, 2, BloodF↑, 3, BMD↑, 1, BP↓, 12, BP∅, 1, CRP↓, 4, GutMicro↑, 6, GutMicro∅, 1, Hcy/homoC↓, 13, Hcy/homoC↝, 1, HemoG↑, 1, hs-CRP↓, 1, IL6↓, 9, LDH↓, 3, PSA↓, 1, TG/TAG↓, 1, VitD↑, 1,

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1, AntiCan↑, 2, AntiDiabetic↑, 2, AntiTum↑, 3, ANXi↓, 2, cardioP↑, 5, chemoP↑, 3, cognitive?, 1, cognitive↓, 1, cognitive↑, 68, cognitive↝, 2, cognitive∅, 12, fatigue↓, 2, GFR↓, 1, GFR∅, 1, hepatoP↑, 5, memory↑, 23, memory∅, 1, Mood↑, 7, motorD↑, 9, MusCon↓, 1, neuroP↑, 12, Obesity↓, 2, Pain↓, 8, QoL?, 1, QoL↑, 10, RenoP↑, 3, Risk↓, 5, Risk↑, 2, Risk↝, 1, Sleep↑, 6, Strength↑, 4, toxicity?, 1, toxicity↓, 31, toxicity↑, 1, toxicity↝, 3, toxicity∅, 7, Wound Healing↑, 1,

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 2, AntiViral↑, 4, Bacteria↓, 2,
Total Targets: 227

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Cancer Database Query Results

Pathway results for Effect on Cancer / Diseased Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

Metal & Cofactor Biology(tgid=2) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Barriers & Transport(tgid=15) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Protein Aggregation(tgid=19) ⓘ

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

Metal & Cofactor Biology(tgid=2) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Barriers & Transport(tgid=15) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Synaptic & Neurotransmission(tgid=18) ⓘ

Protein Aggregation(tgid=19) ⓘ

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Home Page